期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 119, 期 1, 页码 106-108出版社
BLACKWELL PUBLISHING LTD
DOI: 10.1046/j.1365-2141.2002.03881.x
关键词
acute lymphoblastic leukaemia; Philadelphia chromosome; imatinib mesylate; central nervous system; blood-brain barrier
类别
A 32-year-old woman with relapsed Philadelphia chromosome-positive acute lymphoblastic leukaemia was treated with imatinib mesylate (formerly STI571), a selective inhibitor of BCR/ABL tyrosine kinase. Although the initial marrow response was good and stably maintained, she subsequently relapsed with extensive infiltration of leukaemic cells into the central nervous system (CNS). After controlling her CNS disease with additional intrathecal chemotherapy, we measured the concentration of imatinib in cerebrospinal fluid (CSF) and blood simultaneously. The concentration of imatinib in CSF was about 92-fold lower than that in blood. These results suggest that imatinib poorly penetrates the blood-brain barrier and has limited activity against CNS leukaemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据